Ignite Creation Date:
2024-05-06 @ 6:50 PM
Last Modification Date:
2024-10-26 @ 2:56 PM
Study NCT ID:
NCT05809050
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-04-12
First Post:
2023-03-30
Brief Title:
Study of miRNA-155 in Acute Leukemia
Sponsor:
Sohag University
Organization:
Sohag University
Study Overview
Official Title:
Study of miRNA-155 in Acute Leukemia
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The leukaemias are a heterogeneous group of blood cancers Acute leukaemia AL is caused by malignant proliferation of blood cells arrested at an immature stage of development They are very aggressive diseases that run a rapidly fatal course if not promptly diagnosed and appropriately treated Misdiagnosis is very common with delay in diagnosis and prompt treatment being the causes of high morbidity and mortality in acute leukaemias
Although with the continuous improvement of clinical and laboratory diagnosis and treatment methods the prognosis of AML has been significantly improved but there are still about 70 of patients who cannot survive more than 5 years after diagnosis The activity of miRNAs in tumors is regulated by the same alterations affecting protein-coding genes such as chromosomal rearrangements genomic amplifications or deletions or mutations abnormal transcriptional control dysregulation of epigenetic changes and defects in the biogenesis machinery A typical chromosomal rearrangement is a chromosomal translocation especially in hematological malignancies in which it promotes tumor development and progression by the promoter exchange or by the creation of chimeric genes translated as fusion proteins In Acute Myeloid Leukemia AML patients with myeloidlymphoid leukemia gene or mixed-lineage leukemia MLL rearrangement by large-scale genome-wide microarray analysis it was demonstrated that among 48 selected miRNAs 47 of them are increased
Although with the continuous improvement of clinical and laboratory diagnosis and treatment methods the prognosis of AML has been significantly improved but there are still about 70 of patients who cannot survive more than 5 years after diagnosis The activity of miRNAs in tumors is regulated by the same alterations affecting protein-coding genes such as chromosomal rearrangements genomic amplifications or deletions or mutations abnormal transcriptional control dysregulation of epigenetic changes and defects in the biogenesis machinery A typical chromosomal rearrangement is a chromosomal translocation especially in hematological malignancies in which it promotes tumor development and progression by the promoter exchange or by the creation of chimeric genes translated as fusion proteins In Acute Myeloid Leukemia AML patients with myeloidlymphoid leukemia gene or mixed-lineage leukemia MLL rearrangement by large-scale genome-wide microarray analysis it was demonstrated that among 48 selected miRNAs 47 of them are increased
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None